ADBiotech Co., Ltd.
Financials
Valuation Metrics
ADBiotech Co., Ltd.'s Market Cap is ₩560B. At end of 2025 it was ₩632B. Ranked #1597 of 2,410 in KR market (top 66%), #940 of 1,631 on KOSDAQ (top 58%), #176 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 76%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 55.96B KRW | KR#1,597/2,410 Sec#176/231 |
| Revenue | 12.57B KRW | KR#2,246/2,410 Sec#170/231 |
| Net Income | -3.55B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 53.93B KRW | KR#2,170/2,410 Sec#195/231 |
| Net Assets | 26.46B KRW | KR#2,208/2,410 Sec#202/231 |
| Employees | 57 | KR#1,981/2,410 Sec#177/231 |
| Value | ||
| P/B | 2.12x | KR#2,030/2,410 Sec#156/231 |
| P/S | 4.45x | KR#2,141/2,410 Sec#144/231 |
| FCF Yield | -3.03% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -13.42% | KR#1,992/2,410 Sec#152/231 |
| ROA | -6.59% | KR#1,993/2,410 Sec#147/231 |
| Op. Margin | -35.09% | KR#2,186/2,410 Sec#155/231 |
| Revenue Growth | 4.45% | KR#1,227/2,410 Sec#121/231 |
| Financial Health | ||
| Debt Ratio | 103.81% | KR#1,588/2,410 Sec#182/231 |
| Total Debt | 27.08B KRW | KR#1,271/2,410 Sec#99/231 |
| FCF | -1.70B KRW | KR#1,318/2,410 Sec#104/231 |
| Cash | 12.11B KRW | KR#1,575/2,410 Sec#131/231 |
| Current Ratio | 1.09x | KR#1,612/2,410 Sec#162/231 |
| Performance | ||
| 1Y Return | -52.87% | KR#1,777/2,410 Sec#154/231 |
| 1M Return | -12.51% | KR#151/2,410 Sec#12/231 |
| From 52W High | -54.99% | KR#1,299/2,410 Sec#101/231 |
| 1Y MDD | -65.78% | KR#1,757/2,410 Sec#150/231 |
| Trading | ||
| Volume | 51,745 shares | KR#1,541/2,410 Sec#158/231 |
| Trading Value | 94.0M KRW | KR#1,863/2,410 Sec#196/231 |
| Foreign Own. | 1.05% | KR#2,011/2,410 Sec#198/231 |
| Per Share | ||
| EPS | -114 KRW | KR—/2,410 Sec—/231 |
| BPS | 850 KRW | KR#2,327/2,410 Sec#217/231 |
Company Info
Addbio Tech, established in 2000 and headquartered in Chuncheon-si, Gangwon-do, is an eco-friendly biotechnology company researching immune antibodies to develop vaccines and antibiotic alternatives. The company possesses key pipelines, including IgY immune egg yolk antibodies, VHH antibodies, microbial agents, and scFv antibodies, ensuring high stability through both egg-derived and camelid-derived antibody technologies. Addbio Tech is developing products to meet the growing demand for livestock infectious disease solutions and vaccine alternatives, actively expanding its global market presence, particularly through China and Southeast Asia.